Medicure Inc. · TSXV:MPH
Medicure — Investor Presentation (November 2017)
18 slides from Medicure's investor presentation, Nov 21, 2017
Slide 1: Investor Presentation
Investor Presentation November 21st, 2017 Albert Friesen Chair, President & CEO James Kinley CFO
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-loo
Slide 3: Medicure
Medicure A pharmaceutical company focused on the development and commercialization of therapeutics for the U.S. hospital market. Key Attributes: • U.S. hospital sales force with cardio focus • Proven success with growth of Aggrastat® franchise • Expanding portfolio through product development and ac
Slide 4: AGGRASTAT Net Revenue Growth
AGGRASTAT Net Revenue Growth AGGRASTAT Net Revenue (CDN Millions) $35,000,000 $30,000,000 $25,000,000 $20,000,000 $15,000,000 $10,000,000 $5,000,000 $0 2012 2013 2014 2015 2016
Slide 5: Adj. EBITDA Growth
Adj. EBITDA* Growth Consolidated Adj. EBITDA (CDN Millions) $12,000,000 $9,500,000 $7,000,000 $4,500,000 $2,000,000 -$500,000 -$3,000,000 2012 2013 2014 2015 2016 * The Company defines EBITDA as "earnings before interest, taxes, depreciation, amortization and other income or expense" and Adjusted EB
Slide 6: Quarterly Net Revenue
Quarterly Net Revenue Consolidated Quarterly Net Revenue (CDN Millions) 10,000,000 8,000,000 6,000,000 4,000,000 2,000,000 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2012 2013 2014 2015 2016 2017
Slide 7: AGGRASTAT Hospital Demand
AGGRASTAT® Hospital Demand Total Units Sold 30,000 25,000 Label 20,000 Change Oct 2013 15,000 10,000 5,000 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2012 2013 2014 2015 2016 2017
Slide 8: AGGRASTAT Patient Market Share
AGGRASTAT ® Patient Market Share Estimated Patient Market Share 100% (GP IIb/IIIa Inhibitors) 80% 52% 60% Aggrastat (tirofiban HCl) Integrilin (eptifibatide) 40% Reopro (abciximab) 20% 0% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2012 2013 2014 2015 2016 2017
Slide 9: U.S. GP IIb/IIIa Inhibitor (GPI) Market
U.S. GP IIb/IIIa Inhibitor (GPI) Market 2016 GPI Market = $200 Million USD (WAC* Hospital Sales) Aggrastat Market Positioning: • Significant platelet inhibition profile • Robust data in over 8,000 patients Aggrastat Integrilin • Class 1 guideline recommended1,2 $122.2 million $32.5 million • Numerou
Slide 10: Acute cardiovascular hospital product
Acute cardiovascular hospital product • I.V. platelet inhibitor; binds to GP IIb/IIIa receptor • Indicated for Acute Coronary Syndrome (ACS) • 41% reduction in death and MI in high-risk patients1 • Launched by Merck in 1998 • U.S. rights acquired by Medicure in 2006 • Medicure obtained broader FDA a
Slide 11: FDA Approval: Bolus Vial
FDA Approval: Bolus Vial Aggrastat is now available as a concentrated bolus vial u Pre-mixed, single bolus delivery* u Formulated for convenient IV push u No pump programming needed u Relatively neutral pH u Does not require refrigeration * Current 100 mL and 250 mL (both 50 mcg/mL) bag formats prov
Slide 12: Apicore Transaction Summary
Apicore Transaction Summary Acquired 5% interest in Apicore for role in Apicore for role in structuring majority interest purchase and July 2014 financing of Apicore. Also received opAon to acquire remaining shares at a fixed price for 3 years. Excercies opAon to acquire majority interest (60%) of Api
Slide 13: Product & Business Development
Product & Business Development § Building a pharmaceutical portfolio focused on the U.S. cardiovascular market § Leveraging our sales infrastructure § 3 ANDAs in the pipeline for generic cardiovascular drugs § Investing in reduced risk - high reward development projects (ANDAs) and acquisitions (Pre
Slide 14: Prexxartan Overview
Prexxartan Overview Prexxartan is an angiotensin II receptor blocker (ARB) indicated for: • Hypertension in adults and children six years. • Heart failure – reduces hospitalization for heart failure in patients who are unable to swallow valsartan tablets Product Format: Oral Solution Expected Approv
Slide 15: Product & Business Development
Product & Business Development ü 3 ANDAs in the pipeline for generic cardiovascular drugs On Market Medicure Product Pipeline 2017 2017 2017 2017 2018 2018 2018 2018 2019 2019 2019 2019 2020 2020 2020 2020 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 AGGRAST AT PREXXART AN ANDA 1 ANDA 2 ANDA 3
Slide 16: Key Financial Info – MPH: TSXV
Key Financial Info – MPH: TSXV Cap Structure As of November 20th, 2017 Basic Total 15,770,327 Fully Diluted Total 17,823,794 Share Price C$8.35 Market Cap C$131.7M § Recent Financial Highlights* • 2016 Net Revenue $30.0 M • 2016 Adj. EBITDA $9.0 M • Q3 2017 Net Revenue $7.0 M • Q3 2017 Adj. EBITDA $
Slide 17: Thank you
Thank you Contact a Product Specialist Investor Relations 1.800.509.0544 [email protected] 1.888.435.2220 (Ext. 228) For More Information www.medicure.com www.aggrastat.com
Slide 18: Aggrastat Prescribing Information
Aggrastat Prescribing Information Indication: AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). Dosag